68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients

Show simple item record

dc.contributor.author Sathekge, Mike Machaba
dc.contributor.author Lengana, Thabo
dc.contributor.author Modiselle, Moshe
dc.contributor.author Vorster, Mariza
dc.contributor.author Zeevaart, Jan Rijn
dc.contributor.author Maes, Alex
dc.contributor.author Ebenhan, Thomas
dc.contributor.author Van de Wiele, Christophe
dc.date.accessioned 2018-01-12T06:42:49Z
dc.date.available 2018-01-12T06:42:49Z
dc.date.issued 2017-04
dc.description.abstract BACKGROUND : To report on imaging findings using 68Ga-PSMAHBED- CC PET in a series of 19 breast carcinoma patients. METHODS : 68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinely performed staging examinations and analyzed as to lesion location and progesterone receptor status. RESULTS : Out of 81 tumor lesions identified, 84% were identified on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC SUVmean values of distant metastases proved significantly higher (mean, 6.86, SD, 5.68) when compared to those of primary or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011). SUVmean values of progesterone receptor-positive lesions proved not significantly different from progesterone receptornegative lesions. SUV values derived from FDG PET/CT, available in seven patients, and 68Ga-PSMA-HBED-CC PET/CT imaging proved weakly correlated (r = 0.407, p= 0.015). CONCLUSIONS : 68Ga-PSMA-HBED-CC PET/CT imaging in breast carcinoma confirms the reported considerable variation of PSMA expression on human solid tumors using immunohistochemistry. en_ZA
dc.description.department Nuclear Medicine en_ZA
dc.description.librarian am2018 en_ZA
dc.description.sponsorship Department of Nuclear Medicine at University Pretoria and NECSA. en_ZA
dc.description.uri https://link.springer.com/journal/259 en_ZA
dc.identifier.citation Sathekge, M., Lengana, T., Modiselle, M. et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 689-694. https://doi.org/10.1007/s00259-016-3563-6. en_ZA
dc.identifier.issn 1619-7070 (print)
dc.identifier.issn 1619-7089 (online)
dc.identifier.other 10.1007/s00259-016-3563-6
dc.identifier.uri http://hdl.handle.net/2263/63510
dc.language.iso en en_ZA
dc.publisher Springer en_ZA
dc.rights © The Author(s) 2016. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/). en_ZA
dc.subject 68Ga-PSMA en_ZA
dc.subject PET/CT en_ZA
dc.subject Breast cancer en_ZA
dc.subject Prostate-specific membrane antigen (PSMA) en_ZA
dc.subject Positron emission tomography (PET) en_ZA
dc.title 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record